Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2

blonca9
Mar 11
1 min read

Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight